Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis

BACKGROUND: We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chest
Main Authors: Lamattina, Anthony M., Taveira-Dasilva, Angelo, Goldberg, Hilary J., Bagwe, Shefali, Cui, Ye, Rosas, Ivan O., Moss, Joel, Henske, Elizabeth P., El-Chemaly, Souheil
Formato: Artigo
Idioma:Inglês
Publicado em: American College of Chest Physicians 2018
Assuntos:
Diffuse Lung Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224706/
https://ncbi.nlm.nih.gov/pubmed/30144422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.08.1029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados